Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1995-09-08
2004-08-10
Priebe, Scott D. (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024100, C536S024500
Reexamination Certificate
active
06774118
ABSTRACT:
TECHNICAL FIELD
The field of this invention is therapeutic treatment of disease with double stranded nucleic acids which bind transcription factors.
BACKGROUND
A wide variety of diseases result from the over- or under-expression of one or more genes. Given cells may make insufficient amounts of a protein (e.g. insulin) or too much of a protein, be it a normal protein (e.g. TNF), a mutant protein (e.g. an oncogene), or a non-host protein (e.g. HIV tat). The ultimate goal of therapeutic intervention in such diseases is a selective modulation of gene expression.
A variety of methods of transcriptional modulation in vitro have been reported including the use of anti-sense nucleic acids capable of binding nascent message, intracellular immunization with dominant negative mutants.
With the broad potential therapeutic applications, massive efforts have been extended by prominent laboratories and clinics around the world to extend these methods in vivo. To date, the transcription factor decoy strategy has never been successfully adopted in vivo.
Relevant Literature
Description of the roles of transcription factors may be found in Nevins,
Science
258, 424-429 (1992); Dalton,
EMBO J
. 11, 11797 (1992); Yee et al. ibid. 6, 2061 (1987), Weintraub et al.,
Nature
358, 259-261 (1992), Pagano et al.,
Science
255, 1144-1147 (1992). Viral coat protein-liposome mediated transfection is described by Kaneda et al.,
Science
243, 375 (1989). Ritzenthaler et al. (1991)
Biochem J
280, 157-162; Ritzenthaler et al (1993)
J Biol Chem
268, 13625-13631; Bielinska et al.,
Science
16, 997-1000 (1990) and Sullenger et al.,
Cell
63, 601-608 (1990) describe inhibition of transcription with double stranded nucleic acids.
A general discussion concerning the mechanism of restenosis may be found in Libby et al.,
Circulation
86, III-47 (1992) and Clowes et al.,
J. Cardiovasc. Pharmacol
. 14, S12-15 (1989).
SUMMARY OF THE INVENTION
The invention provides for the therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signalling or to viral genes. Methods and compositions are provided for blocking the capacity of endogenous trans-activating factors to modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection.
The methods comprise administering to a patient double stranded nucleic acid “decoys” in a form such that the decoys are capable of entering target cells of the patient and specifically binding an endogenous transcription factor, thereby competitively inhibiting the transcription factor from binding to an endogenous gene. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. Depending on the transcription factor, the methods can effect up- or down-regulation of gene expression. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.
REFERENCES:
patent: 5264423 (1993-11-01), Cohen et al.
patent: 5276019 (1994-01-01), Cohen et al.
patent: 5286717 (1994-02-01), Cohen et al.
patent: 5631237 (1997-05-01), Dzau et al.
patent: 5683985 (1997-11-01), Chu et al.
patent: 5821234 (1998-10-01), Dzau
patent: WO 91/11535 (1991-08-01), None
patent: WO 92/18522 (1992-10-01), None
patent: WO 93/03770 (1993-04-01), None
patent: WO 93/14768 (1993-08-01), None
patent: WO 95/11684 (1995-04-01), None
patent: WO 95/11687 (1995-05-01), None
Morishita et al. “In vivo gene transfer into intact blood vessels: a novel and efficient method”, Circulation 86 (4)(Suppl. I): 1-227, Oct. 1992.*
E. Uhlmann et al. Chem Rev. ('90) 90(4) 543-584.
J. Milligan et al. J. Med. Chem ('93) 36(14) 1923-37.
C. Stein et al. Science ('93) 261: 1004-12.
B. Tseng et al. Cancer Gene Therapy ('94) 1(1):65-71.
P.Hug et al. Biochim. Biophys. Acta ('91) 1097:1-17.
R. Mannino et al. Biotechniques ('88 ) 6(7) 682-90.
R. Schwartz et al. Mayo Clin. Prog. ('93) 68:54-62.
H. Hunchinson et al Circulation Suppl. I ('92) 86 (11) I-226.
K. Chien et al. Science ('93) 260: 916-17.
E. Rubin et al. TIG ('94) 10(6) 199-204.
M. Barinaga Science ('94) 265: 738.
P. Libby et al. Circulation ('92) 86 (Suppl. III): III-47-III-52.
R. Schwartz et al.
Mayo Clinic Proceedings, vol. 68 ('93) pp. 54-62.
K. Chin. Science, vol. 260, ('93) pp. 916-917.
Trends in Genetics ('94) vol. 10, #6, pp. 199-204 P. Libby et al.
Circulation, vol. 86, #6 (Dec. '92) pp. III-47-III-52.
M. Barinaga, Science, vol. 265 ('94) p. 738.
R. Mannino et al. Bio Techniques, vol. 6, No. 7 ('88) pp. 682-690 M. Ostrowski et al.
Mol. Cell. Biol., vol. 3, #11 ('83) pp. 2045-2057 P. Hug et al.
Biochem. Biophys. Acta, vol. 1097, pp. 1-17 (1991).
E. Uhlmann et al. Chemical Reviews, vol. 90, #4 ('90) pp. 543-584.
N. Torita et al. Biochem. Biophys. Res. Comm. vol. 186, #('92) pp 129-134.
H. Wu et al., Gene, vol. 89 ('90) pp. 203-209.
S. Hiebert et al. PNAS USA. vol. 86 ('89) pp. 3594-3598.
R. Mulligan Science, vol. 260 (May 14 '1993) pp. 926-932.
Chu et al., “The Stability of Different Forms of Double-Stranded Decoy DNA in Serum and Nuclear Extracts,”Nucleic Acids Research, vol. 20, pp 5857-5858, 1992.
Dzau et al., “Fusignic Viral Liposomes for Gene Therapy in Cardiovascular Diseases,” vol. 93, pp. 11421-11425, 1996.
Eck et al., “Inhibition of Phorbol Ester-Induced Cellular Adhesion by Competitive Binding of NK-Kappa B In Vivo,”Molecular and Cellular Biology, vol. 13, pp. 6530-6536, 1993.
Kawauchi et al., “Gene Therapy for Attenuating Cardiac Allograft Arteriopathy Using Ex Vivo E2F Decoy Transfection by HVJ-AVE-Liposome Method in Mice and Nonhuman Primates,”Circulation Research, pp 1063-1068, 2000.
Mann et al., “Ex-Vivo gene Therapy of Human Vascular Bypass Grafts with E2F Decoy: The Prevent Single Centre,”Randomised Controlled Trial, vol. 354, pp 1493-1498, 1999.
Medford et al., “Inhibition of TNF-Alpha Induced Vascular Cell Adhesion Molecule-1 Gene Expression in Human Vascular Endothelial and Smooth Muscle Cells Using Transcriptional Factor Decoys,”Circulation, American Heart Association, vol. 88, pp 177, 1993.
Morishita, R. et al., “A Gene Therapy Strategy Using a Transciption Factor Decoy of the E2F Binding Site Inhibits Smooth Muscle Cell Proliferation in Vivo”,Proc. Natl. Acad. Sci.U.S.A., vol. 92, No. 13; pp 5855-5859; 1995.
Mudryj., M. et al., “A Role for the Adenovirus inducible E2F Transcription Factor in a Proliferation Dependent Signal Transduction Pathway,”EMBO Journal, vol. 9, No. 7; pp 2179-2184, 1990.
Bielinska et al., “Regulation of Gene Expression with Double-Stranded Phosphorothioate Oligonucleotides”,Science, 250:997-999 (1990).
Dalton, “Cell Cycle Regulation of the Human cdc2 Gene”,The EMBO Journal, 11(5): 1797-1804 (1992).
Kanea et al., “Increased Expression of DNA Cointroduced with Nuclear Protein in Adult Rat Liver”,Science, 243:375-378 (1989).
Nevins, “E2F: A Link Between the Rb Tumor Suppressor Protein and Viral Oncoproteins”,Science, 258:424-429 (1992).
Pagano et al., “Association of cdk2 Kinase with the Transcription Factor E2F During S Phase”,Science, 255:1144-1147 (1992).
Ritzenthaler et al., “Regulation of the &agr;1(l) Collagen Promoter via a Transforming Growth Factor-&bgr; Activation Element”,J. of Biological Chemistry, 268(18):13625-13631 (1993).
Ritzenthaler et al., “Transforming-growth-factor-&bgr;Activation Elements in the Distal Promoter Regions of the Rat &agr;1 Type 1 Collagen Gene”,Biochem. J.,280:157-162 (1991).
Sullenger et al., “Overexpression of TAR Sequences Renders Cells Resistant to Human Immunodeficiency Virus Replication”,Cell, 63:601-608 (1990).
Weintraub et al., “Retinoblastoma Protein Switches the E2F Site from Positive to Negative Element”,Nature, 358:259-261 (199
Dzau Victor J.
Gibbons Gary H.
Morishita Ryuichi
Dreger Ginger R.
Heller Ehrman White & McAuliffe LLP
Priebe Scott D.
The Brigham and Women's Hospital Inc.
LandOfFree
Therapeutic use of CIS-element decoys in vivo does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic use of CIS-element decoys in vivo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic use of CIS-element decoys in vivo will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3286223